ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
10 announcements with these filters
Cohance Lifesciences completed a USFDA inspection at its Jaggaiahpet API facility, receiving a Form 483 with five observations. The company has initiated corrective and preventive actions.
Cohance Lifesciences invested USD 10 million (₹95 Crore) into its subsidiary NJ Bio, Inc. to subscribe for new Compulsorily Convertible Preferred Stock.
Cohance Lifesciences Limited conducted its 8th Annual General Meeting on 17 September 2026. All resolutions proposed in the notice were passed by the requisite majority.
Cohance Lifesciences completed a USFDA inspection of its Shamshabad formulation plant, receiving a Form 483 with four observations. The company is initiating corrective measures.
Cohance Lifesciences announced a $18 million investment across two subsidiaries, NJ Bio and Aruka Bio, to strengthen its ADC strategy and commercial integration.
Cohance Lifesciences has submitted its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26 in compliance with SEBI regulations. The report is available on the website.
Cohance Lifesciences Limited submitted its Integrated Annual Report for FY 2025-26. The report includes the notice for the company's 8th Annual General Meeting.
Cohance Lifesciences Limited will conduct its 8th Annual General Meeting on 17 September 2026 via video conference. The agenda includes adopting financial statements and director reappointment.
Cohance Lifesciences has withdrawn its credit ratings from CRISIL Ratings Limited for certain loan facilities. The company continues to maintain valid ratings from India Ratings.
DSP Trustee Pvt Ltd sold 2,899,996 shares of Cohance Lifesciences Ltd via open market. The total holding decreased from 4.29% to 3.53%.